Co-Authors
                                
                                
                                    This is a "connection" page, showing publications co-authored by Sandra Belij-Rammerstorfer and Brian Angus.
                                
                                
                                
                                    
                                        
                                                
    
        
        
        
            Connection Strength
            
                
            
            0.346
         
        
        
     
 
    
        
        - 
            Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 Jun; 27(6):1113.
            
            
                Score: 0.059
             
- 
            Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Jun; 27(6):1116.
            
            
                Score: 0.059
             
- 
            Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 02; 27(2):279-288.
            
            
                Score: 0.057
             
- 
            T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 02; 27(2):270-278.
            
            
                Score: 0.057
             
- 
            Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
            
            
                Score: 0.057
             
- 
            Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
            
            
                Score: 0.056